newsfilter
← Latest News
GlobeNewswire·

Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update

Promising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient enrollment continues in the Phase 1b/2